Navigation Links
Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital

Daniel J. Nevrivy, Ph.D., a Washington, D.C. patent attorney, today announces the formation of Nevrivy Patent Law Group P.L.L.C., a law firm focused on biotechnology and pharmaceutical patent law that aims to help businesses, universities and inventors protect their intellectual property (IP) and preserve their capital.

WASHINGTON (Business Wire EON) December 16, 2008 -- The credit crisis and economic downturn pose extraordinary challenges for many of the nation's leading innovative companies who now find themselves with limited access to dwindling pools of capital to fund their innovation and development needs. "These organizations are finding themselves in a difficult situation, because while they recognize that investments in IP can generate a lot of long term value down the road, they must preserve their capital today to stay in business long enough to reap those rewards. The limited access to capital is forcing companies to make difficult choices about what projects to develop and what to put on hold or abandon," according to Dr. Nevrivy. Research universities are also feeling the pinch, hampered by anticipated budget shortfalls and endowments that have been hard hit by the fall in the stock market.

The fees required to obtain patents and build a valuable portfolio, or identify and analyze competitor patents, can be a very costly and significant expense for many organizations. In addition, billing rates for patent attorneys have soared in recent years, due in large part to increases in salaries and other overhead costs that firms have tried to pass along to clients. "Many law firm cost structures which have been built up over the last several years are not really in sync in today's market with businesses' needs. Businesses are trying to get a better handle on managing their costs because they want to preserve their capital to further their innovation and development goals. It is not clear that they will be able to raise additional capital in the near future," according to Dr. Nevrivy.

With this in mind, Dr. Nevrivy founded the new firm, located in the Georgetown area of Washington, D.C. Dr. Nevrivy, who holds a Ph.D. in molecular and cellular biology, was formerly with the D.C. firm of Sterne, Kessler, Goldstein & Fox for seven years. Dr. Nevrivy is building a team of lawyer-scientists to serve businesses, universities and inventors who seek innovative ways to lower their costs for protection of their IP without sacrificing quality.

"It's a little tricky for existing law firms to lower their fees and maintain quality because the cost structure is so built in to their way of doing things. However, a new law firm that is small and highly focused can create a cost structure de novo that works. A reduced overhead and a streamlined firm structure also mean that attorneys can provide the highest quality of work more efficiently than larger firms. It's a win-win situation, for the client and the lawyer," according to Dr. Nevrivy.

About Nevrivy Patent Law Group P.L.L.C.:

Nevrivy Patent Law Group P.L.L.C. ( is alaw firmfocusedon biotechnology and pharmaceutical patent lawthat strives to provide high quality, value-oriented legal services for clients. The firm's services include the preparation, filing and prosecution of patent applications in the U.S. and foreign countries. The firm also conducts due diligence, patentability, invalidity and non-infringement investigations and opinions in a wide variety of subject areas in biotechnology and the pharmaceutical sciences. The firm's services also include client counseling regarding intellectual property matters, including patents, trademarks and trade secrets. The firm also advises clients regarding the transfer and enforcement of intellectual property rights.


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
2. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
3. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
4. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
5. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
6. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
7. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
8. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
9. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
10. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
11. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
Post Your Comments:
Related Image:
 Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital 
(Date:11/30/2015)... ... 2015 , ... Live Very Well is excited to announce ... . The multi-carrier insurance exchange platform offers individual vision and dental ... compare, quote and match plans to meet their needs. , Beginning December ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
(Date:11/30/2015)... ... 30, 2015 , ... Stress, anxiety, illness, infection or even a need for ... , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in ... to tumors. , “Bad headaches that don’t go away, that don’t have ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... ... 30, 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences ... Jurassic to their collection of interactive exhibits within the Kids In Charge! building. In ... guests to get closer than ever to a range of animals as they drink, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015   Royal Philips (NYSE: ... industry,s first MRI guided user interface and automatic scan ... with MR Conditional implants, such as knee and hip ... Radiological Society of North America Annual Meeting (RSNA) . ... diagnostic confidence of this growing patient population. ScanWise Implant ...
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord Blood ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... 2,917 , (3.3) Gross Profit 395,857 , ...
Breaking Medicine Technology: